<DOC>
	<DOCNO>NCT02282982</DOCNO>
	<brief_summary>This non-interventional , prospective , multi-center study control group design assess effectiveness palivizumab population infant high-risk serious Respiratory Syncytial Virus ( RSV ) illness ( infant bear ≤ 35 week gestation infant ≤24 month Bronchopulmonary Dysplasia ( BPD ) Congenital Heart Disease ( CHD ) ) . Participants receive immunoprophylaxis RSV season , define October 2014 April 2015 , routine clinical setting throughout Russian Federation .</brief_summary>
	<brief_title>Observational Program Assess Respiratory Syncytial Virus ( RSV ) Hospitalization Rate Population Children High-risk Serious RSV Illness Who Received Palivizumab Immunoprophylaxis</brief_title>
	<detailed_description>Participants receive intramuscular injection palivizumab accord physician ' prescription local label . The local label recommend 1 month injection interval 5 sequential injection dose 15 mg/kg . Participants could receive 3 5 monthly injection palivizumab 2014 - 2015 RSV season duration study .</detailed_description>
	<mesh_term>Palivizumab</mesh_term>
	<criteria>Planned prescription palivizumab immunoprophylaxis RSV season participant palivizumab prescribe receive first dose palivizumab later 60 day enrollment study Infants high risk severe RSV infection define fulfil least one following : Infants bear ≤35 week gestational age AND ≤6 month age onset RSV season ; Infants ≤24 month age AND diagnosis BPD ( define oxygen requirement correct gestational age 36 week ) ; Infants ≤24 month age hemodynamically significant CHD , unoperated partially correct . Written authorization use individual data sign parent child representative Major congenital malformation aside CHD Chronic pulmonary disease BPD Acute period infection Contraindication palivizumab prescription accord local label Administration product possibly contain RSVneutralizing antibody within 30 day prior enrollment current administration ( include , restrict , follow : RSV hyperimmunoglobulin , polyclonal intravenous immunoglobulin , cytomegalovirus hyperimmunoglobulin , varicella zoster hyperimmunoglobulin )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>2 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Immunoprophylaxis</keyword>
	<keyword>Palivizumab</keyword>
</DOC>